- Raised $28.5M Series B led by RA Capital Management, Sep 2024
- Raised $11M Series A led by Agate, Oct 2021
- Raised $3M grant, Oct 2021
About
Innoventric is an Israeli medical device company committed to addressing the complexities of tricuspid regurgitation (TR) with transcatheter TR solutions. They are leaders in cross-caval technologies and are dedicated to the ongoing development of advanced devices to extend the reach of TR treatment. Their approach is data-driven and grounded in clinical research. Innoventric holds a robust patent portfolio in cross-caval technologies and aims to improve patient care for those with structural heart disease. Their treatments are designed to benefit a broad spectrum of patients, making high-quality care more accessible and improving health outcomes. The company's device addresses TR by replacing the native valve's function through a heterotopic, cross-caval approach, anchoring a prosthetic valve to the vena cava instead of the beating heart.
Funding history · 4 rounds · $42.5M total
Headcount over time
Q&A
- What is Innoventric's primary focus?
- Innoventric is an Israeli medical device company focused on developing transcatheter solutions for tricuspid regurgitation (TR) and right heart disease.
- When was Innoventric founded?
- Innoventric was founded in 2017.
- What is Innoventric's employee count?
- Innoventric has 22 employees, falling within the 11-50 employee bucket.
- What is Innoventric's total funding to date?
- Innoventric has raised a total of $45,200,000 USD across multiple funding rounds.
- When did Innoventric secure its Series B funding round and who were the lead investors?
- In October 2024, Innoventric secured a Series B round of $28,500,000. Lead investors included RA Capital Management and European Investment Committee (EIC).
- When did Innoventric receive a grant from the European Commission?
- In June 2021, Innoventric received a grant of $2,900,000, with the European Commission.
- Who are the co-founders of Innoventric?
- The co-founders of Innoventric are Amir Danino (CEO), Rafi Benary (Head of Business Development), and Dr. David Planer (CMO).
- What is Innoventric's approach to treating tricuspid regurgitation?
- Innoventric addresses TR by replacing the native valve's function through a heterotopic, cross-caval approach, anchoring a prosthetic valve to the vena cava instead of the beating heart.
Team · 3
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | innoventric.com |
|---|---|
| linkedin.com/company/42845988 |
Identifiers & details
| Legal name | Innoventric Ltd. |
|---|---|
| Founded | 2017 |
| Employees (exact) | 22 |
Radar intelligence
Patents
| EPO | 6 |
|---|
Web history (Wayback)
| Domain | innoventric.com |
|---|
Certificate / subdomain footprint
| Subdomains | 8 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 515405256 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2016-02-15 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2025 |
| Active charges / liens | 0 |
| Registry events | 2 — people (1), shares_capital (1) |
| Registered address | הולצמן חיים 1 רחובות |
Recent registry events
| Date | Event |
|---|---|
| 2025-11-25 | עדכון בעלי תפקידים |
| 2025-07-18 | הקצאת מניות |